Navigation Links
Nephros Strengthens Commercialization Team with Addition of Marketing Executive
Date:4/21/2008

NEW YORK, April 21 /PRNewswire-FirstCall/ -- Nephros, Inc. (AMEX: NEP), a medical device company specializing in the treatment of end-stage renal disease, today announced that it has named Joleen C. Turner to be Vice President of Marketing and Business Development, effective today.

In this role, Ms. Turner, an experienced international marketing executive, will lead the development of Nephros's marketing strategy, identifying new markets and channels, and applying the creative use of new media communications.

"I am pleased to welcome Joleen to the Nephros team," Nephros CEO Norman J. Barta said. "Joleen's experience and expertise solidify the company's commercialization resources as Nephros pursues its goal of aggressively expanding product sales."

Ms. Turner's appointment comes as Nephros plans the launch of its OLpur(TM) H2H(TM) Hemodiafiltration Module and OLpur(TM) MD 220 Hemodiafilter products in the United States, subject to receiving the requisite regulatory approvals.

Ms. Turner has 20 years of international experience in strategic marketing, product development and product commercialization with high technology, professional service and life-science corporations. Since June 2006, she has been an independent consultant working with companies such as Boehringer Ingelheim, Pfizer, and Pepsico. She recently led the marketing and packaging launch of a leading respiratory combination drug with revenues now exceeding US $1 billion.

Previously Ms. Turner held the position of Director, Strategic Programs, for Aris Global, a leader in life-science safety and regulatory technology solutions, where her strategic marketing initiatives contributed to the company's record growth and success in the regulatory an
'/>"/>

SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
2. PolyRemedy Strengthens Executive Team With Additions of Diane Cooper, PhD, and Joe Coyne
3. LifeMasters Strengthens Capital Structure with $15 Million in Funding from Existing Investors
4. DuPont Strengthens Leading Biotechnology Position with Leadership Changes
5. Greenway Medical Technologies Strengthens Industry Leadership With Participation in the IHE Connectathon and HIMSS Interoperability Showcase
6. ESFs EMRC strengthens training course on clinical trials management
7. HEALTHeCAREERS Network Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
8. Heraeus Strengthens Medical Components Business
9. MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million
10. Dowden Custom Media Strengthens e-Media
11. Scientx USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... raise your risk for high blood pressure, a new study ... lived within 109 yards of a busy road had a ... women living at least half a mile away, researchers report. ... of our physical environment on our health and well-being," said ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay News) -- ... may face an increased risk of dying in the next several ... older Americans, researchers found those who were unable to detect scents ... as likely to die in the next five years, versus those ... the inability to distinguish odors -- was a bigger predictor of ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... have a total of 500 confirmed cases of Enterovirus D68, ... since the summer, U.S. health officials reported Wednesday. Four ... but it,s not clear what role -- if any -- ... officials are also trying to determine if the virus is ...
(Date:10/1/2014)... University of Adelaide have developed a model that could ... outcome from treatment - from their very first psychotic ... of factors, including clinical symptoms, cognitive abilities, MRI scans ... blood. , Speaking in the lead up to World ... Psychiatry , Professor Bernhard Baune , says ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Predicting the future course of psychotic illness 2Health News:Eighty percent of bowel cancers halted with existing medicines 2
... citrus fruits rich in Vitamin C such as papaya, oranges ... research has found that the nutrient could help reduce ... ,Researchers from the University of Warwick have found that the ... in diabetics. ,Free radicals are tissue-damaging molecules, and ...
... and smoke-free work environment play key roles in helping people ... a study has found. ,The study was ... environmental factors are more influential than individual behaviours and beliefs ... researcher Jon Macy, said that though smoking cessation attempts often ...
... , ... ... ... clutches? Even fetuses in wombs experience stress! Stress can stem from a variety of causes-relationships, job, school and daily activities-just about anything. ...
... Working in an environment where smoking is allowed is especially ... that is not considered safe at any level, a ... by researchers at the Multnomah County Health Department and Oregon ... elevated levels of the carcinogen NNK, which is found in ...
... led by a Children's Hospital of Eastern Ontario (CHEO )researcher ... to vitamin D deficiency Rickets. Despite the fact that generation ... supplements and sunshine, vitamin D deficiency rickets has persisted in ... disease that weakens the leg bones and stunts growth, the ...
... death rates for men from the rural areas are 10 ... ,Despite The fact that cancer survival rates are improving overall, ... death rate of men living in rural areas and their ... in Australia has risen from 78,857 new cases in 1996 ...
Cached Medicine News:Health News:Smoke-free Workplace, Non-smoking Spouse Help Quitters Stay Off the Butt 2Health News:Living With Stress 2Health News:Living With Stress 3Health News:Living With Stress 4Health News:Secondhand Workplace Smoke Hits Non-smokers Badly 2Health News:Vitamin D Deficiency Still Persists in Babies 2Health News:Cancer Deaths of Rural Men on the High 2
(Date:10/2/2014)... --  Intarcia Therapeutics, Inc. today announced successful top-line ... trials for ITCA 650 (exenatide, delivered continuously once or ... first trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 ... ITCA 650 in patients with type 2 diabetes against ... superior to placebo for both 40 mcg and 60 ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: